Haddock BJ, Zhu Y, Doyle SP, Abdullah LH, Davis CW. Role of MARCKS in regulated secretion from mast cells and airway goblet cells. Am J Physiol Lung Cell Mol Physiol 306: L925-L936, 2014. First published April 14, 2014 doi:10.1152/ajplung.00213.2013.-MARCKS (myristoylated alanine-rich C kinase substrate) is postulated to regulate the passage of secretory granules through cortical actin in the early phase of exocytosis. There are, however, three proposed mechanisms of action, all of which were derived from studies using synthetic peptides representing either the central phosphorylation site domain or the upstream, NH2-terminal domain: it tethers actin to the plasma membrane and/or to secretory granules, and/or it sequesters PIP2. Using MARCKS-null mice, we probed for a loss of function secretory phenotype in mast cells harvested from embryonic livers and maturated in vivo [embryonic hepatic-derived mast cells (eHMCs)]. Both wild-type (WT) and MARCKS-null eHMCs exhibited full exocytic responses upon Fc⑀RI receptor activation with DNP-BSA (2,4-dinitrophenyl-BSA), whether they were in suspension or adherent. The secretory responses of MARCKS-null eHMCs were consistently higher than those of WT cells, but the differences had sporadic statistical significance. The MARCKS-null cells exhibited faster secretory kinetics, however, achieving the plateau phase of the response with a t½ ϳ2.5-fold faster. Hence, MARCKS appears to be a nonessential regulatory protein in mast cell exocytosis but exerts a negative modulation. Surprisingly, the MARCKS NH2-terminal peptide, MANS, which has been reported to inhibit mucin secretion from airway goblet cells (Li Y, Martin LD, Spizz G, Adler KB. J Biol Chem 276: 40982-40990, 2001), inhibited hexosaminidase secretion from WT and MARCKS-null eHMCs, leading us to reexamine its effects on mucin secretion. Results from studies using peptide inhibitors with human bronchial epithelial cells and with binding assays using purified mucins suggested that MANS inhibited the mucin binding assay, rather than the secretory response.
MARCKS; exocytosis; mast cells; airway goblet cells; mucin secretion; MANS peptide CELLULAR PRODUCTS, exported from the secretory pathway following cell activation by an extracellular agonist or other signal, are released by regulated, Ca 2ϩ -dependent exocytosis. Our understanding of the final steps of this process, the docking, tethering, and priming of SNARE proteins and their regulation by SM (Sec1/Munc18 family) proteins, is highly advanced (11, 30, 53) . Similarly, the fusion of secretory vesicles/granules with the plasma membrane under the regulation of synaptotagmins is relatively well understood (9, 34, 61) . Indeed, studies utilizing purely synthetic components to reconstitute vesicle-vesicle fusion ex vivo are now revealing reaction intermediates and kinetics within the system (e.g., Ref. 18) . The initial steps of regulated exocytosis, however, are not well known, particularly the transit of secretory granules from the cytosol, through the layer of cortical actin filaments underlying the plasma membrane, to exocytic docking sites on the plasma membrane.
Cortical actin filaments separate secretory vesicles/granules from the near-membrane compartment and have been postulated to act as a passive barrier in exocytosis. This barrier hypothesis originated from observations that cytochalasins, latrunculins, phallotoxins, jasplakinolide, and other reagents that disrupt or stabilize actin filaments (44, 49) frequently stimulate or inhibit secretion, respectively (see Ref. 62) . In both mast cells and the SPOC1 mucin-secreting cell line, for instance, actin filament disruption by cytochalasin, latrunculin, or gelsolin (applied exogenously to permeabilized cells) stimulates exocytosis, and stabilization with phalloidin or jasplakinolide is inhibitory (8, 12, 24, 37) . As noted in a seminal review on the role of actin in exocytosis (31) , however, either such reagents used with other secretory cells have no effect, or the qualitative effect is dependent on reagent concentration. Mucin secretion from goblet cells in human airway epithelial cell cultures, for example, is refractory to cytochalasin D and latrunculin-A (11) , and in PC-12 neuroendocrine cells secretion is stimulated at low latrunculin-B concentrations but is inhibited at high concentrations (15) . Such inconsistent results suggest that actin may play multiple roles in regulating exocytosis, a notion supported by recent research using advanced microscopy and fluorescent reagents in living secretory cells. Conventional myosins I and II; nonconventional myosins, myosin Va in particular; and the Rho small GTPases have been implicated in secretory granule/vesicle movements in the near membrane environment associated with exocytosis (see Refs. 11, 31, 39, 40, 43, 57) . Additionally, in alveolar type II cells and vascular endothelial cells, the exocytic release of surfactant and von Willebrand factor, respectively, appears to be dependent on the formation of a coat of actin filaments around the "secretory granule" immediately following opening of the fusion pore, with the fused "granule" being physically compressed to express its contents (36, 39, 40) . In light of this work, cortical actin is now viewed as working with myosins and regulatory proteins to play a more active role in exocytosis, one that offers elements of selectivity and specificity that might not be expected for a purely passive barrier. Nonetheless, an exocytic barrier function is implicit for cortical actin filaments, purely from the observation that vesicle/granule transport through this zone requires dynamic actin filament remodeling: existing actin filaments are broken down to allow passage of secretory granules, as new filaments form and transit them to docking sites.
Two proteins, scinderin and MARCKS (myristoylated alanine-rich C kinase substrate), have been suggested to disrupt actin filaments during exocytic remodeling (58) . Scinderin, or adseverin, is a Ca 2ϩ -activated, actin filament-severing, -capping, and -nucleating protein, closely related to gelsolin and enriched in secretory tissues, for which there is substantial evidence favoring a role in exocytosis in several cell types (57, 59) , including SPOC1 cells (12) . MARCKS has been suggested to reversibly tether actin filaments to membranes and/or regulate their turnover; however, its relationship to exocytosis is not well established and it is the focus of this paper.
MARCKS is a widely distributed, if not ubiquitous, 80-kDa protein that possesses little definite secondary structure in solution. Its cellular function centers on a small effector or phosphorylation site domain (PSD) located near the middle of the sequence that is rich in basic and aromatic residues and contains four serines, three of which are phosphorylated by PKC (2, 7, 52) . In the inactive protein, the combined hydrophobic and electrostatic forces contributed by the N-myristic acid and the PSD, respectively, cause MARCKS to bind to the inner leaflet of the plasma membrane, and after PKC phosphorylation the protein is freed from the membrane and translocates to the cytosol (2, 5, 7) . Following translocation, the cytosolic localization of MARCKS is vague; it may associate with lysosomes and/or other vesicular compartments (4), including secretory granules (16) . The one other member of the protein family, MacMARCKS or MARCKS-related protein (MRP), exhibits a similar cellular behavior (27, 55) .
Peptides representing the MARCKS PSD bind actin filaments, in vitro (2, 17) , an observation suggesting that MARCKS may tether actin filaments, reversibly, to the plasma membrane; upon cell activation cortical actin would be disrupted as MARCKS translocates to the cytosol (57, 58) . Alternatively, MARCKS PSD peptides have also been shown to bind PIP 2 , in vitro, suggesting that MARCKS may sequester the phosphoinositide in the plane of the plasma membrane of resting cells (32, 63) . In this scenario, cell activation and MARCKS translocation would lead to the mobilization of PIP 2 , which has many known effects on actin dynamics (66) and cell signaling (35) . A third alternative arises from observations with a different synthetic peptide, MANS, representing the first 24 NH 2 -terminal residues of MARCKS, including the NH 2 -terminal myristic acid modification. The MANS peptide causes an apparent inhibition of secretion from airway goblet cells and leukocytes (28, 56) . In this case, MARCKS is suggested to tether secretory granules to actin filaments for transport to membrane docking sites (see Ref. 16) , possibly in concert with HSP70 (13) . Interestingly, as disparate as these proposed functions for MARCKS in exocytosis may appear, the possibilities are not necessarily mutually exclusive. All three possible mechanisms, however, suffer a common weakness: they were all derived from observations using synthetic peptides. For this paper, we took advantage of the availability of a MARCKS-null mouse to ask, simply, whether there is a loss-of-function phenotype for the intact protein in exocytosis. Since the perinatal lethality exhibited by the MARCKS-null mutation (51) precluded working with the airways of adult mice, we studied the secretory competence of mast cells harvested from embryos and maturated in vivo. Because the MANS peptide proved to have unexpected effects on mast cells from MARCKS-null mice, we also reexamined the effects of the peptide on mucin secretion from human goblet cells in primary, human bronchial epithelial (HBE) cell cultures.
Despite their differences in terms of developmental origin, mast cells and goblet cells are both secretory cells, eukaryotic cells specialized to maximize their secretory pathway to synthesize, store, and exocytically secrete their respective cellular products, inflammatory proteases/mediators, and mucins, respectively (11, 20) . Consequently, both cell types depend on the SNARE and SM proteins of the core vesicle trafficking machinery for exocytosis (11, 23, 30, 53) , and exocytosis for both is Ca 2ϩ dependent (33, 34) . From the data in hand, it is likely that the exocytic machinery in these two cells is more similar than different and that any differences are most likely to be due to differences in the specific isoforms involved in the SNARE/SM complex and its regulation, and in second messenger pathways, e.g., how intracellular Ca 2ϩ is handled (11, 30) .
MATERIALS AND METHODS
Mouse mast cell isolation and culture. MARCKS ϩ/Ϫ mice were kindly provided by Drs. Deborah Stumpo and Perry Blackshear, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC. These animals were bred on a C57/BL6J background and raised at the University of North Carolina, allowed food and water ad libitum until euthanized. All experimental procedures using mice were conducted under protocols approved by the University of North Carolina Institutional Animal Care and Use Committee.
Bone marrow-derived mast cells (BMMCs) were generated from bone marrow isolated from the femurs of 6-to 10-wk-old WT mice, and embryonic hepatic-derived mast cells (eHMCs) from homogenized livers of embryonic day 14 -18 embryos harvested from wildtype (WT) mice or their MARCKS-deficient or MRP-deficient littermates; MRP-deficient and littermate WT embryonic livers were made available by Drs. Stumpo and Blackshear (NIEHS). In each case, the resulting cell isolates were cultured in "complete medium," consisting of RPMI 1640 medium supplemented with L-glutamine, 10% FBS, 1 M HEPES buffer, nonessential amino acids, sodium pyruvate, ␤-mercaptoethanol, penicillin/streptomycin, 20 ng/ml IL-3 (Peprotech), and 20 ng/ml murine stem cell factor (SCF; Peprotech, Rocky Hill, NJ) and incubated at 37°C in a 5% CO2 atmosphere (6, 65) . Nonadherent cells from these cultures were resuspended into fresh media every 3-4 days, and adherent cells and materials were discarded. After 4 -5 wk the suspended, presumptive mast cells were assayed for the presence of the Fc⑀RI on the cell surface, a marker of mature mast cells (22) .
Immunohistochemical analyses of mast cell purity and maturation. Five-week-old mast cells were allowed to adhere overnight to fibronectin-coated glass coverslips contained in six-well plates. Medium was then removed and the cells were rinsed with Siraganian buffer (SG buffer: 119 mM NaCl, 5 mM KCl, 25 mM PIPES, 5.6 mM glucose, 1 mM CaCl2, 0.4 mM MgCl2, and 0.1% BSA), blocked for 1 h at room temperature with a mouse CD32/CD16 antibody (1:50) to reduce nonspecific binding to lower affinity Fc receptors, rinsed, and incubated for 1 h with either 1) a primary mouse anti-DNP-BSA IgE antibody (1:25; BD Biosciences, San Jose, CA) followed after rinsing by a 1-h incubation with a secondary rat anti-mouse FITC-anti-IgE antibody (BD Biosciences), or 2) a primary FITC-Fc⑀RI alpha subunit antibody (1:25; eBioscience, San Diego, CA). The cells were then rinsed and fixed with 4% paraformaldehyde in PBS for 7 min and mounted onto glass slides with Prolong Gold Antifade mounting medium (Invitrogen/Life Technologies, Grand Island, NY). Cells were analyzed via a widefield Leica DMIRB inverted microscope with a ϫ40 oil PlanFluor objective (1.25 NA) in the Michael Hooker Microscopy Facility at UNC-Chapel Hill.
In vitro ␤-hexosaminidase secretion assays. Cells (1 ϫ 10 6 /ml) were sensitized overnight at 37°C with DNP-BSA IgE (250 ng/ml, clone SPE-7; Sigma-Aldrich, St. Louis, MO). After sensitization, cells were gently pelleted and resuspended in fresh medium for 24 h prior to activation. For cell-adherent experiments, the cells were incubated in wells coated with fibronectin (20 g/ml). Complete medium was then replaced with 100 l of SG buffer, alone (control), or containing DNP-BSA (1-100 ng/ml; Calbiochem, San Diego, CA) and incubated at 37°C for 30 min, or other time as specified in RESULTS. The secretion-rich medium was then harvested, either by quickly pelleting suspending cells, or simply removing it from adherent cells, then pelleting any cells that may have come free from the substratum. The pelleted, adherent cells were lysed to release the residual ␤-hexosaminidase. ␤-Hexosaminidase activities of the supernatants and lysates were determined using the chromogenic substrate, 4-nitrophenyl N-acetyl-␤-D-galactosaminide, and the amount of secretion for each sample was expressed as a % of total cellular ␤-hexosaminidase [ϭ (hexosaminidase released)/(total hexosaminidase in the supernatant and cell lysate)]. Each measurement was repeated in triplicate, and mean experimental values were calculated from multiple, independent experiments.
Effects of MARCKS-derived, NH 2-terminal peptides on eHMCs. The NH2-terminal myristoylated (MA) peptides, MANS (MA-GAQF-SKTAAKGEAAAERPGEAAVA) and RNS (MA-GTAPAAEGA-GAEVKRASAEAKQAF), were kindly provided by Dr. Kenneth Adler at North Carolina State University, Raleigh, NC, or they were synthesized by the Tufts University Core Facility, Department of Physiology, Boston, MA (website: http://www.tucf.org). The NONG peptide, which possesses the same sequence as the MANS peptide but lacks the NH2-terminal Gly residue to which the myristoyl moiety is normally conjugated, was supplied by the Tufts University facility. Adherent eHMCs were primed with DNP-IgE and allowed to adhere to fibronectin-coated wells of 96-well plates as described above. Fifteen minutes prior to activation, cells were pretreated with SG buffer containing either 50 or 100 M concentrations of MANS, RNS, or NONG; control cells received SG buffer alone. Cells were then activated with 3 ng/ml of DNP-BSA and incubated at 37°C for 30 min, in the continued presence or absence of peptide, and the quantity of ␤-hexosaminidase secreted was determined.
Effects of MARCKS-derived, NH2-terminal peptides on HBE cell mucin secretion. HBE cells were obtained in accordance with Institutional Review Board-approved protocols from normal human bronchi as described (14) . Briefly, HBE cells were isolated and grown on plastic culture dishes in bronchial epithelial cell growth medium (17) and passaged at 80% confluence, and first-passage cells were seeded onto 12-mm, Transwell-Clear supports (Corning Costar, Tewksbury, MA) coated with collagen (Vitrogen, Cohesion, Palo Alto, CA) at 250,000 cells per support. After cell confluence, the cells were maintained under air-liquid interface (ALI) conditions in ALI culture medium (14) , which was changed at the basolateral surface three times a week. HBE cell cultures were used for experiments 4 -6 wk postconfluence, a time when the columnar cells are well differentiated as ciliated or goblet cells.
Mucin secretion experiments and mucin assays (ELISA/ELLA) rigorously followed protocols described previously (1) . Briefly, HBE cell cultures underwent a "careful wash" procedure (1) involving four washes applied to the lumen over an ϳ4-h period to clear accumulated mucus/mucins with minimal mechanical disturbance. The cultures were then incubated for three 30-min periods: the first to establish a baseline, the second to preincubate without or with a MARCKSderived NH2-terminal peptide, and the third to incubate with the agonist, ATP␥S, to stimulate mucin secretion in the continued absence or presence of peptide. After each incubation, the secretions on the culture luminal surfaces were collected by the addition and removal of 400 l DMEM/F12.
Mucins, those purified from HBE cell culture luminal washings, or those in the samples of HBE cell secretions (above), were quantified by adsorption and sandwich ELISA/ELLA protocols. HBE cell mucins were purified from mucus collected from cultures grown for the purpose by use of a standard, double, CsCl gradient equilibrium ultracentrifugation technique (1) . The resulting purified mucins were used to test the effects of MARCKS-derived NH 2-terminal peptides on the binding assays, as well as to generate standard curves on each microtiter plate. All assays utilized flat-bottom, high-binding 96-well microtiter plates (Corning Costar, cat. no. 3590). For "adsorption" assays, purified mucins or HBE cell culture samples were applied straight to the plates. For "sandwich" assays, the plates were first coated with WGA lectin (10 g/ml in PBS, 100 l/well) and incubated overnight at 4°C or 2 h at 37°C, and unbound WGA lectin was washed off before the samples were plated. As detailed in RESULTS, we used three different detection methods: two primary antibodies (ELISAs); a polyclonal mucin-specific, "subunit antibody" (1), the mAb 17Q2 (29, 50) ; or the lectin (ELLA) WGA. The ELISAs were developed by using appropriate horseradish peroxidase (HRP)-conjugated, secondary antibodies; the ELLA used a HRP-conjugated WGA (Sigma, cat. no. 3590). Samples probed with the subunit antibody were reduced and alkylated prior to sample planting. Otherwise, the procedures strictly followed our published protocols (1) .
Statistical analysis. Differences between experimental and control data, at each dose of DNP-BSA, in the mast cell experiments were tested for significance by Student's t-test. The mucin assay results were all assessed by ANOVA, with Dunnett's test for differences.
RESULTS
Model validation for mast cell in vitro maturation and secretion. Mast cells were selected as an appropriate and convenient model for these studies on the basis of their expression of MARCKS (21) , their long use in studies of regulated secretion from nonneuronal cells (26, 45) , and their ready harvest from adult and embryonic tissues and differentiation, in vitro (60) . Typically, mouse mast cell progenitors are harvested from adult bone marrow then differentiated in culture (BMMCs), a source that is impractical when using embryos. Hence, we primarily utilized in vitro differentiated immature mast cells harvested from embryonic livers (eHMCs), using SCF and IL-3, and validated them as mast cells by comparison with BMMCs. The resulting mature BMMCs and eHMC cultures both expressed Fc⑀RI (Fig. 1A) and were Ͼ99% pure. Cells sensitized by an overnight exposure to DNP-BSA IgE, in suspension or adherent to fibronectin-coated surfaces, responded to a subsequent DNP-BSA exposure with a concentration-dependent secretion of hexosaminidase (Fig. 1B) . Note that BMMCs and eHMCs in suspension had very similar secretory profiles to one another, but that the secretory responses of adherent eHMCs were enhanced more than twofold over their suspended counterparts. Additionally, sensitized BMMCs and eHMCs exhibited robust, concentration-dependent responses to ionomycin and concentration-dependent enhancement of ionomycin-induced secretory responses by PMA (data not shown). The magnitude of secretory responses observed, the concentration dependencies, including the domed shape of the DNP-BSA concentration-response curves, and the enhanced secretory responses of adherent cells are all consistent, qualitatively and quantitatively, with reports in the literature from other laboratories (19, 25, 34, 46, 54) .
Effects of MARCKS deficiency on regulated secretion from mast cells. To determine whether MARCKS plays a regulatory role in regulated exocytosis, the secretory responses of eHMCs derived from WT and MARCKS-null mouse embryos to activation of Fc⑀RIs were compared. As shown in Fig. 2 , secretion of hexosaminidase from MARCKS-null mast cells elicited by DNP-BSA was elevated over that secreted by WT cells at most concentrations of DNP-BSA used, whether the cells were in suspension or adherent. However, the variability was sufficiently high to preclude demonstration of statistical significance, except at two concentrations for adherent cells. Hexoaminidase contents of eHMCs derived from both WT and MARCKS-null mice were similar, as shown for adherent cells in Fig. 2B , inset. Importantly, irrespective of statistical significance, note that the response to the absence of the gene was a consistent but marginal elevation in secretory response. It was not the major reduction that might be expected for an essential protein in regulated secretion. Hence, at best, MARCKS appears to modulate mast cell secretion, exerting a modest negative regulation.
Secretion from eHMCs deficient in MRP, the only other member of the MARCKS gene family, was examined to determine whether the observed modulatory effects of MARCKS on mast cell exocytic secretion are specific. In this case, the DNP-BSA concentration-response curves of eHMCs derived from WT and MRP-null mouse embryos were essentially identical (Fig. 3) , suggesting that the effect of MARCKS deficiency to enhance the secretory phenotype, though small, was specific.
Last, the time courses of DNP-BSA-induced secretory responses in WT and MARCKS-null eHMCs were determined to test whether there are kinetic differences in the secretory defect phenotype. Interestingly, hexosaminidase release from MARCKSnull eHMCs was accelerated significantly at the early time points, relative to the release from WT cells. With the data normalized to the maximal hexosaminidase release (at 30 min), the greatest separation between the two datasets occurred at 1 min, but by 5 min, as the responses waned, the two response curves joined Control cells for the latter procedure (right) were exposed only to the secondary antibody. Note the bright ring of fluorescence at the plasma membrane of the cells (arrows), or its absence in the Control. B: after priming with an overnight exposure to DNP-BSA IgE the mast cells were activated with DNP-BSA, over the concentration range shown. The secretory response elicited was determined as the release of hexosaminidase, expressed as the fraction (%) of total cellular hexosaminidase content (means Ϯ SE, n Ն 7, *P Ͻ 0.05, adherent vs. suspended eHMCs). Note the similarity between the concentration dependence to DNP-BSA between bone marrow-derived mast cells (BMMCs) and eHMCs in suspension, and the enhancement by adherence in the eHMC secretory responses.
one another, at ϳ80% of total release (Fig. 4) . Taking this point (5 min) as the end of the fast phase of the response, the t ½ was decreased from a value in WT eHMCs of ϳ1.53 min to 0.62 min in MARCKS-null cells, or approximately a 2.5-fold increase in the rate of release.
In the experiment shown in Fig. 4 , although the rate of hexosaminidase release was increased in the MARCKS-null eHMCs, there was no significant difference in the total amount released between the WT (n ϭ 10) and null (n ϭ 6) cells (0.08 Ͼ p Ͼ 0.05). Likely, this lack of a difference was due to the small magnitude of the increase in secretory response, relative to the variability (Fig. 2) , and/or to the smaller sample size used in the kinetics experiment (Fig. 4) . To examine this possibility formally, the individual data for the hexosaminidase release from the six MARCKS-null eHMCs from the experiments in Fig. 4 were compared systematically against all of the possible 8,008 combinations [n!/(nϪr)!n!] of 16 WT eHMCs used in the experiments for Fig. 2 . The probabilities generated were rank ordered and examined for possible statistical significance: 50.2% of the comparisons between WT and MARCKSnull eHMC total hexosaminidase release would have been considered statistically different (P Ͻ 0.05), and 48.8% would not have been (P Ͼ 0.05). Hence, we conclude that the MARCKS-null phenotype as expressed in regulated mast cell secretion is an exocytic release whose fast phase occurs ϳ2.5-fold more rapidly, but whose magnitude is increased marginally over WT, at most.
Effects of MARCKS-derived peptides on mast cell secretion. The myristoylated, 24-residue synthetic peptide, MANS, representing the NH 2 -terminal sequence of MARCKS, has long been asserted to inhibit the secretion of mucin from goblet cells: exposure of HBE cell cultures to 100 M concentrations of the peptide appear to inhibit mucin secretion, whereas a control, myristoylated peptide, RNS, a myristoylated peptide of the same composition, but randomized sequence, is without effect (16, 28) . The MANS peptide is suggested to compete for specific intracellular MARCKS binding sites, which initiates a series of events that ultimately inhibit migration of secretory granules to the plasma membrane (16, 42) . Since the MANS peptide also appears to inhibit neutrophil degranulation (56), a general involvement of MARCKS in regulated exocytosis has been suggested. The availability of MARCKS-null eHMCs afforded the opportunity to assess an alternative possibility that the inhibition observed represents nonspecific effects of the peptide on the secretory response.
Adherent, primed eHMCs derived from WT and MARCKSnull embryos were preincubated for 15 min with no peptide (control), or 50 and 100 M concentrations of MANS, RNS, or NONG. The latter peptide is a variant of the MANS peptide lacking the NH 2 -terminal Gly and its conjugated myristic acid, and one therefore that should be cell impermeant. The cells were subsequently activated with DNP-BSA in the continued absence or presence of peptide and assessed for possible effects on hexosaminidase release (Fig. 5) . Surprisingly, each of the peptides exhibited a concentration-dependent inhibition of DNP-BSA-activated eHMC secretion from both WT and MARCKS-null cells, with the nonmyristoylated, NONG peptide inhibiting secretion most strongly, by ϳ80%, even at the lower concentration tested. The RNS peptide inhibited secretion slightly, Ͻ15% at 50 M, and strongly, ϳ55-60%, at 100 M. Inhibition of secretion by the MANS peptide was intermediate to the other two. Significantly, in no case did the inhibition by peptide differ in its effects on WT and MARCKSnull eHMCs (Fig. 5) . Also important, none of the peptides had direct effects on hexosaminidase activity in the absence of cells (data not shown). Hence, these data suggest that NH 2 -terminal peptides derived from MARCKS may have nonspecific, extracellular effects on cellular secretion, even when the peptides are most probably restricted to extracellular sites (NONG). Fig. 4 . Effects of MARCKS deficiency on secretory kinetics. Adherent, primed eHMCs from WT (n ϭ 10) and MARCKS-deficient mice (n ϭ 6) were activated with DNP-BSA (3 ng/ml) for 0.5-30 min, as indicated in Fig. 2 , and the secretions were collected at the times indicated. The data are expressed as ␤-hexosaminidase release, normalized to the total amount released at 30 min (*P Ͻ 0.05). Note that the secretory responses of MARCKS-null eHMCs are accelerated over control at the earliest time points. Fig. 3 . Effects of MARCKS-related protein (MRP) deficiency on eHMC secretion. The secretory responses of WT and MRP-deficient eHMC cells to DNP-BSA were uniformly similar (n ϭ 4; not significant), unlike the effects of MARCKS deficiency, which had consistent effects (cf. Fig. 2 ). 2 -terminal peptides on secretion from WT and MARCKS-null eHMCs (Fig. 5) suggested strongly that the inhibitory effects reported for the peptides on mucin secretion from human goblet cells (28) might similarly be nonspecific. Consequently, the effects of the peptides on mucin secretion from HBE cell cultures were examined. However, because preliminary results indicated that the peptides might have additional, direct, and negative effects on the mucin assays utilized in the secretion experiments, this possibility was first investigated in depth. Figure 6 shows the results of a series of mucin microtiter plate binding assays, ELISAs using an antibody that recognizes mucin subunits, each conducted as a dilution series of mucins purified from HBE cell culture secretions by classic, dual CsCl density gradient centrifugations, exactly as is done for the assessment of a standard curve in mucin secretion experiments (1) . The experiments assessed the potential effects of the MARCKS-derived peptides on simple, mucin-adsorption ELISAs, in which the mucin samples are bound directly, by hydrophobic interactions, to the surface of the microtiter plate.
Effects of MARCKS-derived peptides on mucin secretion assays. The clear effects of MANS and related MARCKSderived NH
As shown in Fig. 6A , when the mucins were bound to the microtiter plates first, with the MANS and related peptides added subsequently, there was no apparent effect of any of the peptides: the mucin-antibody response curves all essentially Fig. 6 . Effects of MARCKS-derived peptides on mucin adsorption ELISAs: the order of presentation is important. Mucin ELISAs using a "subunit" polyclonal antibody to polymeric mucins were performed, in which microtiter plates were exposed to the MARCKS-derived peptides (100 M), after (A), before (B), or together with (C) mucin standards [purified human bronchial endothelial cell (HBE) mucins]. As a control to illustrate the effects of detergents on mucin binding (D), the plates were washed with PBS containing Tween 20 (0.05% vol/vol) prior to application of the mucin standards. Color-coded asterisks indicate datasets significantly different from the nopeptide control (*P Ͻ 0.01, n ϭ 6). overlaid the control. However, if the peptides were applied to the microtiter plates first, or presented mixed with the mucins, the two myristoylated peptides, MANS and RNS, had strong, significant, inhibitory effects on the mucin-antibody response curves (Fig. 6, B and C) . Notably, the nonmyristoylated NONG peptide had no effect. Since the microtiter plates used in these ELISAs are designed to adsorb hydrophobic compounds, domains, and/or moieties, this result suggested that the myristoyl groups on the peptides caused the MANS and RNS peptides to bind in such as manner as to block the binding of mucins to the plate. Note that the relatively high concentration of peptide, 100 M, required to achieve (apparent) inhibition of mucin secretion (28) would tend to enhance the blockade. To illustrate this possibility, Fig. 6D shows the results of an adsorption-mucin ELISA in which the detergent, Tween 20, was applied to the plate, then removed by washing, prior to application of the mucin dilution series: the detergent effectively abolished the mucin-antibody response of the assay. These results suggested strongly that the MANS and RNS peptides had potentially negative effects on mucin assays, either in parallel with or to the exclusion of effects on mucin secretion from HBE cell cultures.
Because mucin binding assays utilizing different antibodies or lectins for detection often exhibit different responses (1), we tested the effects of MARCKS-derived peptides on assays using the same antibody, 17Q2, used in the original MARCKSmucin secretion experiments (28) , and WGA, a lectin that binds several glycans that populate mucins, GlcNAc, ␤1-4GlcNAc, ␤1-4GlcNAc, and Neu5Ac (sialic acid) (1). We also tested whether a sandwich binding format would circumvent the problem with the hydrophobic peptide blockade. In the adsorption ELLAs/ELISAs with detection by either WGA or 17Q2, Fig. 7 shows that the myristoylated MARCKS-derived peptides again interfered with the assays when mucins are presented to the microtiter plates with the peptides (Fig. 7, B-1  and D-1) , relative to the controls in which the mucins were plated first (Fig. 7, A-1 and C-1) . When WGA was used for detection, this interference by the peptides in the assays were fully corrected by the use of a sandwich ELLA (Fig. 7, B-2 vs. A-2). When 17Q2 was used for detection, the interference by the RNS peptide was fully corrected by use of a sandwich ELISA; however, the interference of the MANS peptide was only partially corrected (Fig. 7, D-2) . The partial inhibition of the response by MANS in the 17Q2 sandwich ELLA suggests that it may also interfere with the binding of the mAb to some degree.
Unexpectedly, the nonmyristoylated NONG peptide, which did not interfere with the subunit ELISAs (Fig. 6) , did have partial inhibitory effects in the absorption assays with detection by both WGA and 17Q2 (Fig. 7, B-1 and D-1) . Unlike the subunit antibody, which binds nonglycosylated epitopes along the mucin molecule (47), the lectin, WGA, and 17Q2 bind into the glycosylated domains (10, 29, 50) . Hence, it is possible that the NONG peptide interferes in some way with this interaction, but why this inhibition would then be solved by the use of a sandwich assay is not clear (Fig. 7, B-2 and D-2) .
Effects of MARCKS-derived peptides on HBE goblet cell mucin secretion. To test the potential effects of MARCKSderived peptides on experiments determining mucin secretion from airway goblet cells, HBE cell cultures were subjected to a "careful wash procedure" to remove accumulated mucus from their luminal surfaces with minimal mechanical disturbance (1) . Subsequently, the cultures were subjected to three successive, 30-min incubations, 1) with luminal buffer to establish basal mucin secretion; 2) without (Control) or with a MARCKS-derived peptide (100 M); and 3) with ATP␥S, to stimulate mucin secretion, in the continued absence or presence of peptide. The secretions from each period were assessed for mucin content by WGA ELLAs and 17Q2 ELISAs, in both adsorption and sandwich microtiter plate binding formats. Comparing, first, the mucins released during the basal and peptide preincubation periods, there were no apparent effects of the MANS, RNS, or NONG peptides on basal mucin secretion, with the exception of a slight elevation in release in the case of the RNS peptide (which was detected by each of the 4 assays used) (data not shown). The agonist-stimulated mucin secretion data were normalized to the initial, basal secretion period and are presented as box plots in Fig. 8 .
In the absence of MARCKS-derived peptides, ATP␥S had its usual stimulatory effect on HBE cell cultures, increasing mean mucin secretion over basal levels by two-to threefold (1) . Inspecting the distributions of the control data indicated by the box plots in Fig. 8 shows that each of the four assays yielded slightly different results. In part, this variability reflects the different binding characteristics of WGA and 17Q2, as well as the different modes by which the mucins were bound to the plate, i.e., adsorption vs. (WGA) sandwich (1). The control data, however, do have similar distributions within each detection group and are statistically not different when comparing plate binding formats (adsorption vs. sandwich) or method of detection (WGA vs. 17Q2). In contrast, in every case in which the cultures were exposed to a MARCKS-derived peptide, the data yielded by the adsorption binding assays were significantly below the respective controls, irrespective of mode of detection. In the case of the MANS peptide, note that mucin binding to the plate was essentially abolished in the adsorption assays; this inhibition is indicated by the fact that the mean data were not significantly different from zero. Were MANS to have fully inhibited secretion, the values would have instead been equal to 1.0, the level of basal mucin secretion to which the data were normalized.
Interestingly, the RNS peptide, which is also myristoylated, yielded data with the HBE cell secretions quantitatively different from the MANS peptide in the adsorption binding assays. Although the RNS data, too, were significantly lower than both the control and the level of basal secretion, they were significantly higher than the MANS data and different from zero. This difference from the MANS result likely indicates that there are effects of peptide sequence on the adsorption assay, independent of the myristoyl group, or that there are interactions between RNS and nonmucin proteins in the secretions that somehow affect mucin binding. The nonmyristoylated NONG peptide yielded higher values in the adsorption binding assays than either MANS or RNS, values that were similar to the levels of basal secretion. Hence, by the adsorption assays, NONG could be interpreted to have inhibited stimulated mucin secretion, or the peptide had partial effects on the binding of mucins to microtiter plates.
Importantly, the sandwich binding assays yielded data with similar numerical distributions as the controls, regardless of the mode of detection or the presence or absence of MARCKSderived peptides. By these data, neither MANS nor the other two MARCKS-derived peptides appeared to have significant inhibitory effects on agonist-stimulated mucin secretion from HBE cell cultures.
DISCUSSION
Effects of MARCKS deficiency on mast cell secretion. Mast cells, derived from embryonic mouse livers, whether WT or deficient for MARCKS, survived readily in culture and appeared to maturate normally in all basic respects, including, after priming with an IgE to DNP-BSA, a robust secretory response to exposure to the antigen (Figs. 1 and 2 ). The effects of knocking out the MARCKS gene, however, were small and subtle; Fig. 2 shows the magnitude of the secretory response induced by DNP-BSA to be increased marginally in the null eHMCs and significantly so only at a couple of concentrations in the more robustly secreting, adherent cells. A stronger effect was seen in the kinetics of the secretory response, where the MARCKS-null cells responded more quickly than did WT mast cells (Fig. 4) . The effects of MARCKS deficiency do seem specific, however, since there was no apparent effect of knocking out the related family member, MRP (Fig. 3) . Hence, although MARCKS does not seem to be essential for regulated exocytosis from mast cells, it does appear to serve a modulatory function, acting negatively, as a brake on the secretory response to activation of Fc⑀RI.
Effects of MARCKS-derived NH 2 -terminal peptides on secretion. Given the subtle effects of knocking out the MARCKS gene on regulated secretion from eHMCs (Figs. 2  and 4) , the finding that all of the MARCKS-derived NH 2 -terminal synthetic peptides had strong inhibitory effects on WT and MARCKS-null eHMC secretion (Fig. 5 ) was striking. Myristoylated peptides first associate with the plasma membrane and are then internalized into cells by flip-flop diffusion across the plasma membrane or by endocytosis (38) . Hence, the unexpected inhibitory effects of the NONG peptide, which with its lack of myristoylation should be restricted to the extracellular space, are most likely nonspecific. The peptides may inhibit secretion by interfering with Fc⑀RI activation.
Given the effects of the MARCKS-derived peptides on MARCKS-null eHMC hexosaminidase secretion (Fig. 5) , we inferred that the reported effects of MANS on airway goblet cell mucin secretion (28) could be due to nonspecific, extracellular effects of the peptide, rather than the specific effects on intracellular trafficking pathways suggested originally (41, 42) . However, when this possibility of indirect effects was initially tested in preliminary experiments on HBE cell mucin secretion, an internal control included in the ELISA procedures used to measure mucin release indicated that MANS may instead, or may additionally, affect the assay itself. Subsequent experiments testing each of the peptides for effects in our standard, polymeric mucin-specific adsorption ELISA (1) suggested strongly that the myristoylated peptides, MANS and RNS, when presented to the plate either before or mixed with purified mucins, interfered with the binding of mucins, by hydrophobic domains, to the microtiter plates (Fig. 6) .
In the first study to suggest an inhibition of goblet cell mucin secretion by the MANS peptide, mucin release was detected with an antibody capture (sandwich) ELISA by using the mAb 17Q2 (29) as the primary antibody (28) , and this method has been cited in all subsequent studies from the originating laboratory (16) . Unfortunately, the details of the procedure offered were not extensive: no mention was made of the antibody (or Fig. 7 . Comparing the effects of MARCKS-derived peptides on mucin adsorption (left, A-1-D-1) and sandwich (right, A-2-D-2) assays. Mucin standard curves were generated in the absence (Control) or presence MARCKS-derived peptides (MANS, RNS, NONG) in ELLA/ELISA adsorption or sandwich assays, using either the lectin WGA or the antibody 17Q2 for detection. Nonconjugated WGA, adsorbed to the plates, was used as the substratum in the sandwich ELLA assays. Twin assays were conducted for each mode of detection, 1 in which the mucins were bound to the plates prior to application of the synthetic peptide (A and C, mucin 1st, peptide 2nd), and 1 in which the mucins were mixed with the peptides (B and D, mucin ϩ peptide). For clarity, standard errors are shown only for the upper and lower bounding curves; where not visible, they are smaller than the symbols. Asterisks, color-coded to the condition, indicate data (intensities at 500 and 1,000 ng/ml) different from Control (*P Ͻ 0.01, n ϭ 4). Fig. 8 . Comparison of mucin adsorption and sandwich assays in detecting agonist-stimulated mucin secretion from HBE cell cultures. Secretions collected from HBE cultures before and after exposure to agonist (ATP␥S, 100 M, 30 min), were assessed for contained mucins by adsorption and sandwich assay formats, and WGA (A, ELLA) or the mAb 17Q2 (B, ELISA) for detection. For sandwich assays, WGA was also bound to microtiter plates before application of the mucin/peptide samples. The data are displayed, normalized to baseline, as box plots (10, 25, 50, 75 , 90 percentiles); asterisks (*) indicate statistical significance (P Ͻ 0.05; for 17Q2 assays, n ϭ 32 cultures derived from 8 lungs; for WGA assays, n ϭ 11 cultures from 3 lungs). Dotted lines indicate basal secretion levels. lectin?) used for the capture step of the assay; blocking procedures, if used, were not given; purified mucin standards were not used to calibrate the ELISAs; and, most important, the MANS and RNS synthetic peptides were presumably not tested for effects on the mucin binding assays since such a control procedure was not mentioned. It therefore not being possible to duplicate the assay conditions used in these earlier studies precisely, we instead pursued further tests for assay interference by the MARCKS-derived peptides using a combination of adsorption and sandwich ELISAs and ELLAs, using two reagents for detection, 17Q2 and the lectin WGA. As detailed in RESULTS and in Fig. 7 , not only did these results confirm that the myristoylated peptides interfered with mucin binding in the adsorption assays, but there also appeared to be other effects of the peptides in the absorption assays when purified mucins were presented to the plates for binding, mixed with the peptides. For instance, even the nonmyristoylated NONG peptide had inhibitory effects in both the WGA and 17Q2 adsorption assays (Fig. 7, B-1 and D-1) . With the sandwich assays, however, the peptides did not appear to have negative effects, except in the sole case of the MANS peptide: it had a small effect in the WGA sandwich ELLA and a larger effect in the 17Q2 sandwich ELISA (Fig. 7, B-2 and D-2) .
Finally, when these same assays were used to assess the effects of the MARCKS-derived peptides on the ATP␥S-induced, mucin-secretory responses of HBE cell cultures, we found a pattern of inhibitory effects similar to those occurring in the assays (cf., Figs. 7 and 8) . Each of the peptides appeared to inhibit mucin secretion when assessed by adsorption assays, but when the same secretions were assessed instead by sandwich ELLA or ELISA, no effects were apparent. Notably, with the absorption assays, the effects of both MANS and RNS could be ascribed clearly to effects on mucin binding during the assay, rather than to an effect on the goblet cells, since the numeric values were zero, or nearly so. As explained in RESULTS, were secretion inhibited, the values would have instead been close to 1.0. Hence, we conclude that in our hands the MANS peptide has no direct effect on goblet cell mucin secretion and suggest that the inhibitory effects ascribed to the peptide previously (28) may have been due to assay artifacts.
There have been at least two studies with the MANS peptide, however, in which inhibitory effects of MANS were reported from studies of mouse airways in vivo, using assays that estimated mucin secretion indirectly. One assessed periodic acid-Schiff's staining of airway goblet cells to estimate residual mucins following agonist exposure in the absence and presence of peptide (48) . The other assessed airway conductance, to estimate the degree mucous plugging following agonist stimulation of mucin secretion (3) . Although the assays used in these studies are unlikely to be affected by peptiderelated artifacts, the lack of a major secretory phenotype in the MARCKS-deficient mouse suggests that inhibitory effects of the peptides in these studies may have been independent of the MARCKS protein. We have found that there are nonspecific effects of MARCKS-derived peptides on mast cell hexosaminidase secretion that are clearly extracellular (Fig. 5 , NONG peptide), as well as nonspecific effects, both detergent-like and detergent-independent, on mucin binding assays (Figs. 6 and 7), so these peptides appear to have biological activities that are MARCKS independent. Hence, it is conceivable that the peptides may have other activities in the airways.
Role of MARCKS in exocytic secretion. As outlined in the INTRODUCTION, there are three postulated roles for MARCKS in regulated exocytosis: it tethers cortical actin filaments to the plasma membrane and/or secretory granules, and/or it sequesters PIP 2 . The data presented above suggesting that the reported inhibitory effects of the MANS peptide on regulated mucin secretion instead represent an assay artifact may make it unlikely that MARCKS functions to tether actin filaments to secretory granules. Moreover, the subtle enhancement of mast cell secretion resulting from knocking out the MARCKS gene does not allow distinction between the remaining possible mechanisms of action for the protein. In fact, the very subtlety suggests that MARCKS is a nonessential protein for regulated exocytosis and that uncovering its effects could be a major challenge. A potentially important lesson from these studies is that synthetic peptides are prone to artifacts; hence, one hopes that future studies focusing on MARCKS make use of more robust, single-cell techniques, such as the expression from constructs of fluorescently tagged, intact MARCKS proteins, studied by advanced microscopy. An excellent example of such a study recently revealed a beautiful coordination of oscillatory peaks in Ca 2ϩ and granule capture and transport through the cortical actin of RBL cells prior to exocytosis (64) .
